Bio-Rad Q3 Revenues Drop 11 Percent | GenomeWeb

NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market Tuesday an 11 percent decrease in third quarter revenues, including a 13 percent decrease in sales for its Life Science segment.

For the three months ended Sept. 30, Bio-Rad reported revenues of $470 million compared to $530.6 million in the year-ago period, and below analysts’ consensus estimate of $495.6 million. On a currency-neutral basis, Bio-Rad's Q3 revenues decreased 2.2 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.